Shinji Kohsaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shinji Kohsaka has a total of 491 co-authors. Here are the top co-authors by number of shared publications:
- Toshihide Ueno
Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan
134 shared publications - Takafumi Koyama
Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan
129 shared publications - Noboru Yamamoto
Department of Thoracic Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
128 shared publications - Mitsuru Yanagaki
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan
125 shared publications - Kan Yonemori
National Cancer Center Hospital, Tokyo, Japan
121 shared publications - Hitomi Sumiyoshi Okuma
National Cancer Center Hospital, Tokyo, Japan
118 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Efficacy and Safety of Alectinib in Pediatric and Adult Patients with ALK -Altered Advanced Solid Tumors: A Phase II TACKLE Trial (NCCH1712/MK003)
Purpose: Anaplastic lymphoma kinase (ALK) alterations occur in a range of rare malignancies; however, prospective evidence supporting alectinib beyond lung cancer remains limited. We evaluated the activity and safety of alectinib in patients with advanced ALK-altered solid tumors. Patients and Methods: In this open-label, multicenter phase II study, patients with advanced ALK-altered solid tumors received alectinib (capsule or suspension). The primary endpoint was centrally confirmed objective response rate (ORR) per RECIST v1.1, evaluated using a Bayesian design (expected ORR, 40%; threshold, 10%) in patients receiving intact capsules (cohort A). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Results: Twenty-six patients (age, 8 months–78 years) with 11 tumor types were enrolled; inflammatory myofibroblastic tumor (IMT; n = 9) and neuroblastoma (n = 5) were the most common. ALK alterations included fusions/rearrangements (n = 19), mutations (n = 5), and amplifications (n = 2). The median follow-up was 15 months. In cohort A (n = 16 with measurable disease), the centrally reviewed ORR was 43.8%, meeting the primary endpoint. Among evaluable patients (n = 24), the ORR was 54.2%, and the DCR was 75%. The median PFS and OS were 24.9 and 38.8 months, respectively. Patients with ALK fusions/rearrangements (n = 17) had ORR and DCR of 76.5% and 88.2%, respectively. All patients with IMT achieved tumor shrinkage (ORR, 87.5%). Patients ≤15 years (n = 11) had ORR and DCR of 63.6% and 100%, respectively. Grade ≥3 treatment-related adverse events occurred in 15.4% (n = 4), with no treatment-related deaths. Conclusions: Alectinib demonstrated meaningful, durable responses with acceptable safety across ALK-altered solid tumors, particularly in patients with ALK fusions, supporting further tumor-agnostic development.
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Open AccessEfficacy and Safety of Alectinib in Pediatric and Adult Patients with ALK -Altered Advanced Solid Tumors: A Phase II TACKLE Trial (NCCH1712/MK003)
Purpose: Anaplastic lymphoma kinase (ALK) alterations occur in a range of rare malignancies; however, prospective evidence supporting alectinib beyond lung cancer remains limited. We evaluated the activity and safety of alectinib in patients with advanced ALK-altered solid tumors. Patients and Methods: In this open-label, multicenter phase II study, patients with advanced ALK-altered solid tumors received alectinib (capsule or suspension). The primary endpoint was centrally confirmed objective response rate (ORR) per RECIST v1.1, evaluated using a Bayesian design (expected ORR, 40%; threshold, 10%) in patients receiving intact capsules (cohort A). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Results: Twenty-six patients (age, 8 months–78 years) with 11 tumor types were enrolled; inflammatory myofibroblastic tumor (IMT; n = 9) and neuroblastoma (n = 5) were the most common. ALK alterations included fusions/rearrangements (n = 19), mutations (n = 5), and amplifications (n = 2). The median follow-up was 15 months. In cohort A (n = 16 with measurable disease), the centrally reviewed ORR was 43.8%, meeting the primary endpoint. Among evaluable patients (n = 24), the ORR was 54.2%, and the DCR was 75%. The median PFS and OS were 24.9 and 38.8 months, respectively. Patients with ALK fusions/rearrangements (n = 17) had ORR and DCR of 76.5% and 88.2%, respectively. All patients with IMT achieved tumor shrinkage (ORR, 87.5%). Patients ≤15 years (n = 11) had ORR and DCR of 63.6% and 100%, respectively. Grade ≥3 treatment-related adverse events occurred in 15.4% (n = 4), with no treatment-related deaths. Conclusions: Alectinib demonstrated meaningful, durable responses with acceptable safety across ALK-altered solid tumors, particularly in patients with ALK fusions, supporting further tumor-agnostic development.
- Open Access
- 17 July 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (14) , e70360
Interleukin‐1α‐Mediated Activation of TNF ‐α/ NF ‐ κB Signaling Confers Resistance to Osimertinib in EGFR ‐Mutant Non‐Small‐Cell Lung Cancer
Background: Lung cancer is the leading cause of cancer‐related deaths worldwide. Although osimertinib is more effective than previous‐generation drugs, its efficacy is often limited by both primary and acquired resistance. Cycling cancer persister cells (CPCs) have recently emerged as a transient, drug‐tolerant subpopulation that may contribute to early resistance to targeted therapies. However, their biological characteristics and role in osimertinib resistance remain poorly understood. Methods: We established osimertinib‐resistant CPCs derived from epidermal growth factor receptor ( EGFR) ‐mutant non‐small‐cell lung cancer (NSCLC) cell lines PC9 and HCC827. RNA sequencing (RNA‐seq) was performed to identify CPC‐specific transcriptional programs. Results: RNA‐seq analyses demonstrated that the tumor necrosis factor alpha (TNF‐α)/nuclear factor‐κB (NF‐κB) signaling pathway was upregulated in osimertinib‐resistant PC9 cells (PC9‐CPCs), with interleukin‐1 alpha (IL‐1α) being the most significantly overexpressed gene. Treatment with IL‐1α increased TNF‐α and NF‐κB p65 expression in PC9 parental cells, whereas IL‐1α inhibition decreased TNF‐α expression in PC9‐CPCs. Consequently, the inhibition of either IL‐1α or TNF‐α restored the sensitivity of EGFR ‐mutant NSCLC cells to osimertinib. Immunohistochemical analysis confirmed that NF‐κB expression was higher in tumor specimens from patients who had developed osimertinib resistance than in specimens collected before treatment. Conclusion: CPCs exhibit a distinct inflammatory phenotype driven by IL‐1α–driven activation of the TNF‐α/NF‐κB axis, representing an alternative mechanism underlying osimertinib resistance. Targeting IL‐1α or TNF‐α may provide a promising strategy to overcome resistance in patients with EGFR ‐mutant NSCLC.
- 17 July 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (14) , e70360
Open AccessInterleukin‐1α‐Mediated Activation of TNF ‐α/ NF ‐ κB Signaling Confers Resistance to Osimertinib in EGFR ‐Mutant Non‐Small‐Cell Lung Cancer
Background: Lung cancer is the leading cause of cancer‐related deaths worldwide. Although osimertinib is more effective than previous‐generation drugs, its efficacy is often limited by both primary and acquired resistance. Cycling cancer persister cells (CPCs) have recently emerged as a transient, drug‐tolerant subpopulation that may contribute to early resistance to targeted therapies. However, their biological characteristics and role in osimertinib resistance remain poorly understood. Methods: We established osimertinib‐resistant CPCs derived from epidermal growth factor receptor ( EGFR) ‐mutant non‐small‐cell lung cancer (NSCLC) cell lines PC9 and HCC827. RNA sequencing (RNA‐seq) was performed to identify CPC‐specific transcriptional programs. Results: RNA‐seq analyses demonstrated that the tumor necrosis factor alpha (TNF‐α)/nuclear factor‐κB (NF‐κB) signaling pathway was upregulated in osimertinib‐resistant PC9 cells (PC9‐CPCs), with interleukin‐1 alpha (IL‐1α) being the most significantly overexpressed gene. Treatment with IL‐1α increased TNF‐α and NF‐κB p65 expression in PC9 parental cells, whereas IL‐1α inhibition decreased TNF‐α expression in PC9‐CPCs. Consequently, the inhibition of either IL‐1α or TNF‐α restored the sensitivity of EGFR ‐mutant NSCLC cells to osimertinib. Immunohistochemical analysis confirmed that NF‐κB expression was higher in tumor specimens from patients who had developed osimertinib resistance than in specimens collected before treatment. Conclusion: CPCs exhibit a distinct inflammatory phenotype driven by IL‐1α–driven activation of the TNF‐α/NF‐κB axis, representing an alternative mechanism underlying osimertinib resistance. Targeting IL‐1α or TNF‐α may provide a promising strategy to overcome resistance in patients with EGFR ‐mutant NSCLC.
- Open Access
- 8 June 2026
- Published by Elsevier in Lung Cancer
- Vol. 218, 109491
Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan
- 8 June 2026
- Published by Elsevier in Lung Cancer
- Vol. 218, 109491
Open AccessReal-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan
- 27 May 2026
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
Differences Among Genomic Profiling Tests for Bone and Soft-Tissue Sarcomas in a Universal Health Insurance System
Background: Accurate identification of gene fusions is critical for precision oncological approaches to sarcomas, where specific fusion genes are actionable targets of tyrosine kinase (TK) inhibitors. This study provides a descriptive overview of the real-world use, under a universal health insurance program, of 3 different comprehensive genomic profiling (CGP) panels within the Japanese national CGP system: GenMineTOP, which integrates DNA and RNA sequencing, and 2 DNA-based panels, FoundationOne CDx and the OncoGuide NCC Oncopanel System. Methods: We examined 2,633 sarcoma cases from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database to identify potentially actionable alterations classified by the Cancer Knowledge Database (CKDB). The mean patient age was 51.1 years, and 45% were female. Detection rates of TK fusions ( FGFR1-4, NTRK1-3, ALK, RET, ROS1, and BRAF ) were compared descriptively. Additionally, 3 sarcoma cases with an NTRK fusion detected by GenMineTOP were functionally validated. Results: Potentially actionable alterations (CKDB Levels A, B, and C) were identified in 566 patients (21.5%). Actionable TK fusions were detected in 3.1% (8 of 254) with GenMineTOP, 1.4% (31 of 2,211) with FoundationOne CDx, and 0.6% (1 of 168) with NCC Oncopanel. GenMineTOP identified rare NTRK fusions, including RBPMS::NTRK2, HTT::NTRK2, and EML4::NTRK3 . Functional assays suggested their oncogenic potential and demonstrated responsiveness to the TK inhibitors larotrectinib and entrectinib. Conclusions: In this cohort, the DNA+RNA-based panel showed a higher detection rate for TK fusions, although the panels were applied to different patient groups and the sensitivity and specificity could not be determined. Future studies evaluating different test types on the same tumor specimens are warranted to clarify whether the dual-sequencing approaches can improve the identification of actionable genetic events. Level of Evidence: Diagnostic Level IV . See Instructions for Authors for a complete description of levels of evidence.
- 27 May 2026
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
Differences Among Genomic Profiling Tests for Bone and Soft-Tissue Sarcomas in a Universal Health Insurance System
Background: Accurate identification of gene fusions is critical for precision oncological approaches to sarcomas, where specific fusion genes are actionable targets of tyrosine kinase (TK) inhibitors. This study provides a descriptive overview of the real-world use, under a universal health insurance program, of 3 different comprehensive genomic profiling (CGP) panels within the Japanese national CGP system: GenMineTOP, which integrates DNA and RNA sequencing, and 2 DNA-based panels, FoundationOne CDx and the OncoGuide NCC Oncopanel System. Methods: We examined 2,633 sarcoma cases from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database to identify potentially actionable alterations classified by the Cancer Knowledge Database (CKDB). The mean patient age was 51.1 years, and 45% were female. Detection rates of TK fusions ( FGFR1-4, NTRK1-3, ALK, RET, ROS1, and BRAF ) were compared descriptively. Additionally, 3 sarcoma cases with an NTRK fusion detected by GenMineTOP were functionally validated. Results: Potentially actionable alterations (CKDB Levels A, B, and C) were identified in 566 patients (21.5%). Actionable TK fusions were detected in 3.1% (8 of 254) with GenMineTOP, 1.4% (31 of 2,211) with FoundationOne CDx, and 0.6% (1 of 168) with NCC Oncopanel. GenMineTOP identified rare NTRK fusions, including RBPMS::NTRK2, HTT::NTRK2, and EML4::NTRK3 . Functional assays suggested their oncogenic potential and demonstrated responsiveness to the TK inhibitors larotrectinib and entrectinib. Conclusions: In this cohort, the DNA+RNA-based panel showed a higher detection rate for TK fusions, although the panels were applied to different patient groups and the sensitivity and specificity could not be determined. Future studies evaluating different test types on the same tumor specimens are warranted to clarify whether the dual-sequencing approaches can improve the identification of actionable genetic events. Level of Evidence: Diagnostic Level IV . See Instructions for Authors for a complete description of levels of evidence.
- 17 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (4) , 770-781
Germline Pathogenic Variant Prediction Model for Tumor-Only Sequencing Based on Japanese Clinicogenomic Database
Purpose: Germline pathogenic variants (GPV) are frequently identified as secondary findings in cancer gene panel testing. Due to limited data on germline conversion rates (GCR) in the Japanese population, clinical decisions have relied on European Society for Medical Oncology (ESMO) criteria. We aimed to develop a variant-level GCR prediction algorithm using a Japanese tumor–normal matched panel database and compare its utility with existing standards. Experimental Design: We analyzed 7,078 Japanese cases from the NCC Oncopanel dataset, focusing on 32 hereditary cancer genes. Clinical features, sample information, sequence results, and minor allele frequency (MAF) in healthy populations were incorporated into a machine learning model and nomogram. Clinical utility was assessed via decision curve analysis and validated using the GenMineTOP dataset. Results: Among 3,372 cases (mean age 61; 51% male), 4,905 pathogenic variants were identified, including 491 GPV (GCR: 10%). High disease-specific GCR were observed in BAP1 (11% in ocular tumors), BRCA1 and/or BRCA2 (13%–16% in ovarian/peritoneal cancers), and NF1 (16% in peripheral nerve tumors). Genes with >50% GCR included RAD51C, BRCA1, PALB2, CHEK2, RET, BRCA2, and PMS2. Significant predictors included age <30, multiple cancers, gene type, cancer type, MAF, relative variant allele frequency to tumor purity, and tumor allele ratio (TAR). The model achieved a c-index of 0.96 to 0.97, outperforming ESMO (0.88), with a 1.2% net benefit at a 5% threshold. The results were confirmed using the GenMineTOP dataset. Conclusions: Variant-level prediction models for Japanese patients with cancer incorporating TAR and MAF offer improved GPV prediction over gene-level approaches and support clinical decision-making and personalized medicine.
- 17 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (4) , 770-781
Germline Pathogenic Variant Prediction Model for Tumor-Only Sequencing Based on Japanese Clinicogenomic Database
Purpose: Germline pathogenic variants (GPV) are frequently identified as secondary findings in cancer gene panel testing. Due to limited data on germline conversion rates (GCR) in the Japanese population, clinical decisions have relied on European Society for Medical Oncology (ESMO) criteria. We aimed to develop a variant-level GCR prediction algorithm using a Japanese tumor–normal matched panel database and compare its utility with existing standards. Experimental Design: We analyzed 7,078 Japanese cases from the NCC Oncopanel dataset, focusing on 32 hereditary cancer genes. Clinical features, sample information, sequence results, and minor allele frequency (MAF) in healthy populations were incorporated into a machine learning model and nomogram. Clinical utility was assessed via decision curve analysis and validated using the GenMineTOP dataset. Results: Among 3,372 cases (mean age 61; 51% male), 4,905 pathogenic variants were identified, including 491 GPV (GCR: 10%). High disease-specific GCR were observed in BAP1 (11% in ocular tumors), BRCA1 and/or BRCA2 (13%–16% in ovarian/peritoneal cancers), and NF1 (16% in peripheral nerve tumors). Genes with >50% GCR included RAD51C, BRCA1, PALB2, CHEK2, RET, BRCA2, and PMS2. Significant predictors included age <30, multiple cancers, gene type, cancer type, MAF, relative variant allele frequency to tumor purity, and tumor allele ratio (TAR). The model achieved a c-index of 0.96 to 0.97, outperforming ESMO (0.88), with a 1.2% net benefit at a 5% threshold. The results were confirmed using the GenMineTOP dataset. Conclusions: Variant-level prediction models for Japanese patients with cancer incorporating TAR and MAF offer improved GPV prediction over gene-level approaches and support clinical decision-making and personalized medicine.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Criteria for modifying treatment
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Criteria for modifying treatment
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Targeted sequencing analysis of cell-free DNA samples
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Targeted sequencing analysis of cell-free DNA samples